AbbVie stock price forecast: Downside risk builds as ABBV drops 3.07% to $208

Traders Union
All News
Financial News
AbbVie slides 3.07% today to $208.36

Highlights

AbbVie will report Q1 2026 earnings on April 24, with analysts projecting strong year-over-year profit growth and guidance provided.
The company declared a $1.73 quarterly dividend, payable May 15, against a backdrop of recent institutional holding changes and continued share price pressure.
ABBV trades below critical moving averages amid prevailing sell momentum, with bearish signals pointing to a likely $204–$214 trading range over the next week.

Earnings optimism and dividend plans offset by persistent selling pressure

Allergan Aesthetics, an AbbVie company, announced its fourth annual CoolMonth event on March 31, 2026, featuring offers on CoolSculpting®. AbbVie scheduled its fiscal first-quarter 2026 earnings release for April 24, with analyst expectations for substantial year-over-year earnings growth, and provided specific earnings guidance for both the quarter and fiscal year. The company declared a quarterly dividend of $1.73 per share, with a record date of April 15 and a payment date set for May 15, alongside recent institutional adjustments to holdings, though price action has remained under broader selling pressure.

Sellers dominate as momentum weakens and volatility expands intraday

Momentum signals on the daily chart remain under pressure, with the MACD showing a strong sell and the ADX indicating weak trend strength. RSI and CCI are both below midline, while Stoch RSI and BBP have shifted from overbought to oversold levels intraday, pointing to a rapid loss of earlier buying momentum and increasing seller dominance. The price is down 3.07% so far today with no meaningful gap at the open, now trading at the lower end of today’s range; volatility is moderate to high and the session has a clear downward bias. There is notable divergence between oscillators, with overbought readings on some timeframes but waning momentum in others, confirming that sellers are driving the intraday move.

Limited upside as technicals and volatility signal likely consolidation

For the next five trading days, ABBV is expected to trade between $204 and $214, aligning with the typical volatility band relative to current levels. The probability of a price increase is very low (less than 20%), with a price decrease being much more likely based on prevailing daily and weekly indicators. The baseline scenario sees the price consolidating sideways near current levels. A bullish scenario would require a breakout above the $219 immediate resistance, while a bearish scenario could be triggered by a sustained drop below $204, opening up further downside risk.

Viktoras Karapetjanc, Traders Union analyst, notes that ABBV remains under pressure technically, with price and momentum indicators both in a bearish stance. Despite recent corporate developments, strong dividend policy, and earnings optimism, the short-term setup is dominated by seller control and limited upside probability. He sees consolidation as the most likely scenario, given institutional adjustments and the current volatility band. A bullish reversal would need a sustained breakout above $219. "I remain constructive on ABBV’s long-term outlook, but for now patience is required until price action confirms renewed strength above resistance."

Earlier, analysts noted that AbbVie shares were facing persistent downside pressure, with a cautious, sideways outlook prevailing amidst mixed momentum signals. That outlook remains intact as the current price action and technical setup continue to support a predominantly bearish scenario, making a sustained break below $204 an important downside risk for investors to monitor in the days ahead.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.